Skip to main content
CriticalFDAfda-H-0404-2026UNDECLARED ALLERGEN

HerbsForever- Gastro Care; Ayruvedic Herbal Supplement; 90 VEGE Capsules; Extract 800 MG each capsule. UPC: 8 07814 00124 3

⚠ Critical Alert — Stop Using Immediately

This product has been flagged with severe risks (undeclared allergen). Stop using it now and contact the brand or FDA for a refund, repair, or replacement.

Category
Units Affected
45
Recall Date
January 6, 2026
Issuing Agency
Hazard
Undeclared Allergen

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-H-0404-2026.

Potential undeclared allergen ingredient (Wheat)

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-H-0404-2026.

Recall terminated by FDA.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact Herbs Forever or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-H-0404-2026.

Herbs Forever

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

Herbs Forever Recall FAQ

Herbs Forever is the subject of a supplements safety report: HerbsForever- Gastro Care; Ayruvedic Herbal Supplement; 90 VEGE Capsules; Extract 800 MG each capsule. UPC: 8 07814 00124 3. The notice was published on January 6, 2026 by the U.S. Food and Drug Administration (FDA). Approximately 45 units are potentially affected.